Sartorius AG
XETRA:SRT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
168
288
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Sartorius AG
Sartorius AG
Current Portion of Long-Term Debt
Sartorius AG
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sartorius AG
XETRA:SRT
|
Current Portion of Long-Term Debt
€98.8m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
11%
|
|
|
Carl Zeiss Meditec AG
XETRA:AFX
|
Current Portion of Long-Term Debt
€21.8m
|
CAGR 3-Years
7%
|
CAGR 5-Years
19%
|
CAGR 10-Years
24%
|
|
|
Stratec SE
XETRA:SBS
|
Current Portion of Long-Term Debt
€58.9m
|
CAGR 3-Years
53%
|
CAGR 5-Years
35%
|
CAGR 10-Years
43%
|
|
|
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
|
Current Portion of Long-Term Debt
€9.2m
|
CAGR 3-Years
47%
|
CAGR 5-Years
24%
|
CAGR 10-Years
4%
|
|
|
Siemens Healthineers AG
XETRA:SHL
|
Current Portion of Long-Term Debt
€2.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
89%
|
CAGR 10-Years
N/A
|
|
|
Draegerwerk AG & Co KGaA
XETRA:DRW8
|
Current Portion of Long-Term Debt
€40.5m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-10%
|
|
Sartorius AG
Glance View
Sartorius AG, a formidable player in the life sciences industry, has been weaving the fabric of innovation within the biotechnology sector for over a century. Originating in 1870 as a precision mechanics workshop in Göttingen, Germany, the company has blossomed into a global powerhouse in the biopharmaceutical and laboratory equipment market. Central to Sartorius's operations is its focus on providing cutting-edge solutions that streamline lab processes and enhance productivity. By offering essential products like bioreactors and cell culture media, Sartorius plays a pivotal role in accelerating research and production processes for pharmaceutical companies worldwide. Underpinning Sartorius's financial success is its dual-pronged strategy: the Bioprocess Solutions division and the Lab Products & Services division. The Bioprocess Solutions wing caters to the production needs of biopharmaceuticals, delivering equipment and technologies crucial for manufacturing therapies and vaccines. Meanwhile, the Lab Products & Services division offers an array of instruments and consumables pivotal for research and quality control. This strategic alignment allows Sartorius to maintain robust growth by capturing value from both research and industrial production stages in biotech. With a well-orchestrated focus on innovation and expansion, Sartorius has cemented its role as a critical enabler in the biopharmaceutical value chain, continually driving developments that shape the future of medicine.
See Also
What is Sartorius AG's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
98.8m
EUR
Based on the financial report for Sep 30, 2024, Sartorius AG's Current Portion of Long-Term Debt amounts to 98.8m EUR.
What is Sartorius AG's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
11%
Over the last year, the Current Portion of Long-Term Debt growth was -70%. The average annual Current Portion of Long-Term Debt growth rates for Sartorius AG have been -35% over the past three years , -10% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet